Official Title

A Sham Controlled Prospective Randomized Clinical Trial of the RejuvenAir® System for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease with Chronic Bronchitis (SPRAY-CB)

Purpose

The purpose of this study is to determine the safety and effectiveness of a device called the RejuvenAir® System, developed for patients with chronic bronchitis. The primary objective of this trial is to demonstrate the safety and effectiveness of the RejuvenAir® System for the treatment of adult subjects with a diagnosis of CB defined as COPD with classic 3 months of cough and sputum production for a minimum of 2 years who demonstrate ongoing symptoms of cough and significant mucus production. You will be in the study for approximately 36 months, including the screening period.

Could this study be right for you?

Inclusion Criteria: 1. Males and females 40-80 years of age 2. Must demonstrate daily cough and significant mucus production 3. Have had a diagnosis of chronic bronchitis (CB) and chronic obstructive pulmonary disease (COPD) for a minimum of two years. (CB is defined clinically as chronic productive cough for 3 months in each of 2 successive years in a patient in whom other causes of productive cough have been excluded) 4. Smoking history of at least 10 pack years 5. Non-smoking for a minimum of 2 months prior to consent and agrees to continue not smoking for the duration of the study Exclusion Criteria: 1. Have had an acute pulmonary infection, exacerbation or pneumonia requiring medical treatment (with antibiotics and/or steroids) within 4 weeks prior of initially planned study bronchoscopy 2. Diagnosis of Asthma 3. You have had any type of transplant procedure 4. Use e-cigarettes, vaping or inhaled substances not prescribed by a physician RejuvenAir® System 5. You are pregnant, nursing, or planning to get pregnant during study * This is a not a complete list of either inclusion or exclusion criteria

Age Range

40 and up

Official Title

A Double-Blind, Placebo-Controlled Study of Cariprazine as an Adjunct to Antidepressants in the Treatment of Patients with Major Depressive Disorder Who Have had an Inadequate Response to Antidepressants Alone

Purpose

The purpose of this study is to look into the safety and efficacy of cariprazine as an add-on medication in the treatment of major depressive disorder.

Could this study be right for you?

Inclusion criteria:
- Between the ages of 18 and 61
- Currently taking an antidepressant
- Currently experiencing symptoms of depression

Age Range

18 and up

Official Title

Evaluation of the efficacy of radiofrequency-based debridement vs. mechanical debridement for the treatment of articular cartilage lesions.

Purpose

The purpose of this study is to evaluate 2 different treatments, Mechanical Debridement (i.e., a mechanical shaver that removes areas of damaged tissue) and Radiofrequency Debridement (i.e., electrical energy that removes areas of damaged tissue), used to treat the chondral lesion in your knee.

Could this study be right for you?

You may be eligible for this study if you:
• Are 18 - 50 years of age
• Suspected chondral damage in the following locations where debridement is indicated:
o Medial femoral condyle
o Lateral femoral condyle
o Trochlea
o Patella
• 1 or more chondral lesion(s) as noted on MRI

Exclusion:
• Previous chondral treatment in the same compartment (prior debridement and lavage performed more than three months prior to baseline are acceptable)
• Pregnant and/or intending to become pregnant during this study period

Age Range

18 and up

Official Title

A Multicenter, Randomized, Sham-controlled Study to Evaluate Safety and Efficacy After Treatment with the Nuvaira™ Lung Denervation System in Subjects with Chronic Obstructive Pulmonary Disease (COPD)

Purpose

The purpose of this research study is to evaluate the safety and efficacy of the Nuvaira System, which is made by Nuvaira, Inc., for Targeted Lung Denervation (TLD) Therapy.

The primary purpose of conducting this study is to see if TLD Therapy in addition to optimal medical care (daily breathing medications you have been prescribed by your doctor) is better at reducing a moderate or severe worsening of symptoms (known as an COPD flare-ups or exacerbations) and related hospitalizations than optimal medical care (daily breathing medications you have been prescribed by your doctor) alone.

Could this study be right for you?

Inclusion Criteria:
• Between 40 and 75 years of age
• Non-smoking for a minimum of 2 months prior to consent and agrees to not smoke for the duration of the study
• Diagnosis of COPD with 30% ≤ FEV1 <60% of predicted and FEV1/FVC <70% (post-bronchodilator)
• SpO2 of at least 89% on room air at the time of screening
• Has a documented history of having minimally been taking a regular respiratory maintenance medication for at least 12 months at the time of consent; medications will be reviewed by study team
• If you have participated in a formal pulmonary rehabilitation program recently, program completion should have occurred more than 3 months prior to consent; if in a maintenance program, you will agree to continue your current program through your 12-month follow-up visit;
• Additional criteria will be reviewed by the study team

Involvement in this study will last approximately 62 months.

Age Range

40 and up

Official Title

A prospective, randomized, active treatment-controlled, evaluator-blinded (radiologist reviewer and physician evaluator) multicenter study to establish the superiority of a hyaluronan-based scaffold (Hyalofast®) with autologous bone marrow aspirate concentrate (BMAC) in the treatment of articular knee cartilage defect lesions in comparison to control (microfracture treatment)

Purpose

The purpose of this research study is to evaluate an investigational procedure for treatment of damage to the cartilage in your knee, also called a defect or lesion, which requires repair. If eligible, you will receive one of two possible arthoscophy procedures. You may be assigned to receive the study procedure to implant Hyalofast® scaffold in your knee together with cells from your own bone marrow, called Bone Marrow Aspirate Concentrate, or BMAC. Bone marrow is the substance found inside your bones that among other things helps to make blood cells. The other possible procedure is called Microfracture and is one of the current standard of care options to treat your condition.

Could this study be right for you?

-Ages 18 to 60.
-Patient’s body mass index (BMI) is <35 kg/m2
-Patient has a symptomatic lesion of the femoral condyle (medial and/or lateral) or femoral trochlea that is between 1--6 cm2 on screening images confirmed by the independent radiologist
-Patient is using only nonsteroidal anti-inflammatory drugs or acetaminophen/paracetamol during the month before signing the informed consent form to treat knee pain
-Patient is willing to use other pain medication rather than NSAIDS for 6 months post-surgery (e.g. acetaminophen, or narcotic analgesics, if prescribed). Post-surgical use of aspirin for clot prevention is acceptable.
-Patient is willing to restrict pain medication after 6 months post-surgery to NSAIDs or acetaminophen/paracetamol only through the end of the trial
-No history of previous microfracture or other cartilage repair procedure on study knee
-Not currently pregnant or expecting to become pregnant in the next 12 months
-No diagnosis of advanced osteoarthritis

Age Range

18 and up

Official Title

A Phase 3 Prospective, Randomized, Partially Blinded Multi-Center Study to Measure the Safety and Efficacy of NOVOCART® 3D, Compared to Microfracture in the Treatment of Articular Cartilage Defects

Purpose

The purpose of this research study is to evaluate an investigational procedure for treatment of knee cartilage defects. If eligible, you will receive one of two possible surgical procedures. One is the investigational procedure under study, utilizes the Novocart® 3D autologous cartilage implant system. The other possible procedure is called Microfracture and is one of the current standard of care options to treat your condition. Both surgical procedures will be followed by pain and knee function assessments and a course of physical rehabilitation.

Could this study be right for you?

Inclusion Criteria:
--Ages 18-65
•Little response to conservative treatment (non-operative treatments such as physical therapy, weight loss)
•Single articular cartilage lesion on the femoral condyle (round projection at the end of the femur) 2-6 cm2
•BMI less than 40

Exclusion Criteria:
•Instability of the knee joint
•Arthritis
•Autoimmune disease
•Immune suppression
•Prior surgical treatment using mosaicplasty, autologous chondrocyte implantation and/or microfracture (debridement and lavage are acceptable beyond three months from baseline)
•Bone disease
•Any degenerative muscular, connective tissue or neurological condition or other disease process that would interfere with healing or the evaluation of outcome measures.

Age Range

18 and up

Official Title

A Longitudinal Outcomes Study of the Subchondroplasty® Procedure in the Hip

Purpose

To collect outcomes data for patients undergoing the Subchondroplasty® (SCP®) Procedure in the hip. Outcomes to be assessed include medication usage, pain, function, activity levels and patient satisfaction.

Could this study be right for you?

Eligibility Criteria
• 18 years of age or older
• Subchondral bone defect(s) in the hip (femoral head, femoral neck and/or acetabulum) has been confirmed via MRI or x-ray.
• Other requirements reviewed by the physician.

Exclusion Criteria:
• Collapse of the subchondral bone

Age Range

18 and up

Official Title

ABT-CIP-10300: Abbott DBS Registry of Outcomes for Indications over Time (ADROIT)

Purpose

The purpose of this study is to collect information and evaluate outcomes for Abbott Deep Brain Stimulation (DBS) systems that are approved and sold in your country.

In order to evaluate how the DBS system performs, data will be collected before, during and after DBS implant when you visit the study doctor. The data collected will include information on your movements, feelings, daily activities, and DBS program settings.

The information gathered in this study will add to the understanding of treatment options for future patients receiving DBS.

Could this study be right for you?

Inclusion Criteria:

- You are scheduled for a new implant or IPG device replacement surgery with a market-released Abbott DBS system within 3 months

Exclusion Criteria:

- You are currently enrolled or plan to enroll in another study that may alter the results of this clinical investigation
- You have another disease, conditions, or other medical, social, or psychological conditions that could limit the your ability to participate in the clinical investigation or to satisfy follow-up requirements

Official Title

Adjusting to Life After COVID-19

Purpose

This study looks at what is helping people adjust to the changes caused by the COVID-19 pandemic so that we may understand what could help people adapt to crises in the future. This information could benefit with the understanding and improvement of treatments for conditions such as depression and anxiety.

The study will examine the experience of psychological symptoms, adaptability, and coping over time.

Could this study be right for you?

You may eligible for this study if you are:
• 18 years of age or older
• Currently unemployed or laid off
• Be considered high risk if infected with COVID-19 (e.g., being 65 or older or having an underlying health condition).
• Have NOT had a positive COVID-19 test result
• Do NOT have an immunity to COVID-19

Age Range

18 and up

Official Title

Creation of a pediatric healthy control repository for clinical diagnostic immunology test development and validation

Purpose

A test for healthy adults from 19 - 75 years old to develop normal values for interpretation of immunological tests in adults with disorders of the immune system.

Voluntary participation involves blood draw at Nationwide Children's hospital. Qualified participants would be eligible to provide a sample every 2 months (not more than 6 times per year).

Could this study be right for you?

If you are:

- An adult 19 years of age or older
- Healthy with no significant medical diagnoses
- Have no chronic conditions that can affect results of immunological studies
- Not any medication known to alter immune status or function
- Have not undergone recent surgery, chemotherapy, radiation or transplantation
- Non-smoker
- Body mass index (BMI) in healthy range
- No infections within last 2 months

Age Range

19 and up

Official Title

ANB019-003: A Phase II, Randomized, Placebo-controlled, Double-blind, Multiple Dose Study to Evaluate the Efficacy and Safety of ANB019 in Subjects with Palmoplantar Pustulosis

Purpose

This study is being done to assess the effects of the experimental study drug (ANB019) in patients with PPP.

Could this study be right for you?

- Must have a clinical diagnosis of PPP for at least 6 months prior to screening
- Must have active pustules on palms and/or soles of feet
- BMI must be within the range of 18-36 kg/m2
- Subjects must be in otherwise good health
- Must not have any suspected autoimmune disorder or immune deficiency
- No major surgeries in the past 4 weeks
- No history of malignancy in the past 5 years
- No history of drug, alcohol, or other substance abuse

Age Range

18 and up

Official Title

Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent

Purpose

The purpose of the study is to determine if the investigational study drug will rapidly reduce depression associated with thoughts of harming oneself when given in addition to standard antidepressant medication.

Your participation in this study will last for a minimum of 14 weeks and maximum of 58 weeks.

Could this study be right for you?

• Aged 18-65 years old
• Diagnosed with major depressive disorder (MDD) with a current major depressive episode
• Having current suicidal ideation with intent
• Already in the hospital or agree to be hospitalized voluntarily for the required period of time

Age Range

18 and up